Literature DB >> 2913138

Immunotherapy with cat- and dog-dander extracts. IV. Effects of 2 years of treatment.

G Lilja1, B Sundin, V Graff-Lonnevig, G Hedlin, H Heilborn, K Norrlind, K O Pegelow, H Løwenstein.   

Abstract

Thirty-five patients (20 children and 15 adults) with animal-dander asthma completed 2 years of immunotherapy with partly purified and standardized cat- or dog-danger extracts. The first year of the study was performed double-blind with a placebo-treated control group. These 15 patients were transferred to active treatment for a second year. All patients were followed by use of the skin prick test (SPT), allergen and histamine bronchial challenges, and tests for allergen-specific IgE, IgG1, and IgG4 levels. In the group treated with active extracts for 2 years (group A), the previously reported decrease in bronchial responsiveness to cat extract (p less than 0.001) and histamine (p less than 0.01) was even more pronounced after the second year. After 1 year of active treatment in the original placebo group (group B), a significant decrease in the bronchial responsiveness to cat extract was noted (p less than 0.001). The responsiveness to histamine was decreased only in the patients treated with cat-dander extracts (p less than 0.05). A significant decrease in the SPT (p less than 0.001) and an increase in the allergen-specific IgE (p less than 0.001) and IgG4 (p less than 0.001) was also noted in patients (group B) treated with cat-dander extracts. The side effects in the two groups (A and B) were negligible, except for some systemic side effects, especially among the children during the initial phase of immunotherapy. The symptoms were mild and responded promptly to treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913138     DOI: 10.1016/0091-6749(89)90475-2

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  4 in total

Review 1.  Immunotherapy for mold allergy.

Authors:  H J Malling
Journal:  Clin Rev Allergy       Date:  1992

Review 2.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 3.  [Allergen-specific immunotherapy in pet allergy - an update].

Authors:  U Raap; M Wagenmann; O Pfaar
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

Review 4.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.